Koss Olinger Consulting, LLC Grifols Sa Transaction History

Koss Olinger Consulting, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$7.71 - $11.56 $881,784 - $1.32 Million	-114,369 Reduced 85.34%	19,648 $227,000
Q3 2023 Oct 10, 2023	BUY	$8.91 - $10.91 $3,029 - $3,709	340 Added 0.25%	134,017 $1.22 Million
Q2 2023 Jul 28, 2023	BUY	$7.14 - $9.29 $2,527 - $3,288	354 Added 0.27%	133,677 $1.22 Million
Q1 2023 May 12, 2023	SELL	$6.65 - $10.69 $195,669 - $314,542	-29,424 Reduced 18.08%	133,323 $982,000
Q4 2022 Feb 13, 2023	BUY	$5.96 - $8.53 $706,236 - $1.01 Million	118,496 Added 267.78%	162,747 $1.38 Million
Q3 2022 Nov 14, 2022	BUY	$5.95 - $14.3 $263,293 - $632,789	44,251 New	44,251 $273,000

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.31B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Koss Olinger Consulting, LLC, based on Form 13F filings with the SEC.

Stay updated on Koss Olinger Consulting, LLC with notifications on news.